UiPath (NYSE:PATH) Rating Reiterated by Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of UiPath (NYSE:PATH) in a research report sent to investors on Wednesday morning, Benzinga reports.

A number of other equities research analysts have also weighed in on the stock. Morgan Stanley reaffirmed an “equal weight” rating and set a $15.00 price target on shares of UiPath in a report on Friday, September 6th. TD Cowen lowered their target price on UiPath from $17.00 to $16.00 and set a “hold” rating for the company in a research note on Friday, September 6th. BMO Capital Markets boosted their price target on UiPath from $14.00 to $15.00 and gave the stock a “market perform” rating in a research note on Friday, September 6th. Royal Bank of Canada restated a “sector perform” rating and set a $16.00 price objective on shares of UiPath in a research note on Friday, September 6th. Finally, Bank of America upped their target price on UiPath from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Friday, September 6th. Sixteen investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, UiPath presently has a consensus rating of “Hold” and an average target price of $17.47.

UiPath Price Performance

NYSE:PATH opened at $12.35 on Wednesday. The business’s 50-day moving average is $12.50 and its two-hundred day moving average is $14.10. The firm has a market capitalization of $6.79 billion, a PE ratio of -61.75 and a beta of 0.88. UiPath has a 12 month low of $10.37 and a 12 month high of $27.87.

UiPath (NYSE:PATH) last announced its earnings results on Thursday, September 5th. The healthcare company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.03 by $0.01. The business had revenue of $316.00 million for the quarter, compared to the consensus estimate of $303.69 million. UiPath had a negative return on equity of 3.98% and a negative net margin of 8.13%. The company’s revenue was up 10.0% on a year-over-year basis. During the same period last year, the business posted ($0.09) EPS. Equities analysts anticipate that UiPath will post -0.23 EPS for the current year.

Insider Buying and Selling

In other UiPath news, CFO Ashim Gupta sold 47,671 shares of the firm’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $12.07, for a total value of $575,388.97. Following the sale, the chief financial officer now directly owns 849,917 shares in the company, valued at approximately $10,258,498.19. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 22.37% of the stock is owned by company insiders.

Institutional Investors Weigh In On UiPath

A number of hedge funds have recently made changes to their positions in PATH. PNC Financial Services Group Inc. increased its position in UiPath by 50.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 19,135 shares of the healthcare company’s stock valued at $475,000 after acquiring an additional 6,385 shares during the period. Sunbelt Securities Inc. raised its stake in shares of UiPath by 7,602.5% during the first quarter. Sunbelt Securities Inc. now owns 18,178 shares of the healthcare company’s stock valued at $412,000 after purchasing an additional 17,942 shares in the last quarter. Future Financial Wealth Managment LLC acquired a new stake in UiPath in the first quarter worth about $73,000. Wealth Enhancement Advisory Services LLC grew its position in UiPath by 15.3% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 30,479 shares of the healthcare company’s stock valued at $691,000 after buying an additional 4,039 shares in the last quarter. Finally, 180 Wealth Advisors LLC increased its stake in UiPath by 7.2% during the 1st quarter. 180 Wealth Advisors LLC now owns 202,637 shares of the healthcare company’s stock valued at $4,594,000 after buying an additional 13,687 shares during the period. Institutional investors own 62.50% of the company’s stock.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.